Physician profile
Peter G Ehrnstrom
NPI 1689600439
$10,276.75
in general payments reported to CMS, 2019-2025
27 companies · $2,295 in 2025
The $2,295 reported for 2025 was more than what 90% of Mohs-Micrographic Surgery providers received nationally (typical 2025 total: $462).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $917 · 2020: $145 · 2021: $1,152 · 2022: $1,465 · 2023: $1,854 · 2024: $2,448 · 2025: $2,295.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,498 · Education: $99.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,497.96 |
| Education | $99.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $3,281.30 | 2019-2025 | |
| Novartis Pharmaceuticals Corporation | $1,352.39 | 2019-2025 | |
| Janssen Biotech, INC. | $1,225.56 | 2019-2025 | Tremfya |
| E.R. Squibb & Sons, L.L.C. | $731.15 | 2022-2025 | Sotyktu |
| Genzyme Corporation | $665.52 | 2021-2025 | |
| Ucb, INC. | $615.98 | 2019-2025 | Bimzelx, Cimzia |
| Sun Pharmaceutical Industries INC. | $546.98 | 2019-2025 | Ilumya |
| Regeneron Healthcare Solutions, INC. | $398.85 | 2019-2025 | Libtayo, Dupixent |
| Lilly USA, LLC | $291.33 | 2019-2025 | Taltz, Ebglyss, Olumiant |
| Leo Pharma INC. | $198.87 | 2021-2025 | Adbry, Anzupgo |
| Amgen INC. | $136.88 | 2019-2025 | Otezla, Otezla |
| Pfizer INC. | $115.63 | 2019-2023 | |
| Galderma Laboratories, L.P. | $104.92 | 2024-2025 | Nemluvio |
| Arcutis Biotherapeutics, INC. | $98.45 | 2023-2025 | Zoryve |
| Incyte Corporation | $88.44 | 2023-2025 | Opzelura |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Organogenesis INC. | $56.65 | 2022-2025 | Puraply Wound Matrix |
| Kyowa Kirin, INC. | $55.36 | 2023-2024 | Poteligeo |
| Smith+Nephew, INC. | $54.40 | 2019 | |
| Strata Skin Sciences, INC. | $47.29 | 2021-2023 | Xtrac |
| Genentech USA, INC. | $44.23 | 2019-2021 | |
| Dermavant Sciences, INC. | $39.23 | 2023-2024 | Vtama |
| Dusa Pharmaceuticals, INC. | $36.39 | 2019 | |
| Helsinn Therapeutics (U.S.), INC. | $26.81 | 2019 | |
| Biofrontera INC. | $20.67 | 2021 | |
| Mimedx Group, INC. | $16.56 | 2024 | |
| Organon LLC | $15.77 | 2025 | Vtama |
| Merck Sharp & Dohme LLC | $11.14 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Peter Ehrnstrom listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.